Future studies using diverse ways of administering mda-7/IL-24 as a single agent, including viral administration [8,9,10] and T cell mediated delivery [11], and in combination with other therapeutic agents are planned for the near future and suggest that this therapeutic cytokine will provide significant clinical benefit in patients with diverse cancers. This evidence concerns the gene IL24 and cancer.